Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Bernard Escudier, Saby George et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

Max S. Topp, Nicola Gökbuget, Anthony S. Stein et al. · The Lancet Oncology · 2014 · 1.2K citations

Hematological Malignancy, Lymphoid Neoplasia, Oncology +9

Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis.

Thomas A. Drake, James H. Morrissey, Thomas S. Edgington · PubMed · 1989 · 1.2K citations

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda et al. · Journal of Clinical Oncology · 2015 · 1.2K citations

Design of therapeutic proteins with enhanced stability

Naresh Chennamsetty, Vladimir Voynov, Veysel Kayser et al. · Proceedings of the National Academy of Sciences · 2009 · 586 citations · Full text

Protein Chemistry, Engineering, Therapeutic Antibodies +15